Pancreatic Cancer Research

ResearcherFirst Affiliated Hospital of Xi'an Jiaotong UniversityActive in the last 2 years

Weikun Qian

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-8389-5289; OpenAlex author ID A5075443051. Sources: OpenAlex.

Their work

Papers
46 (first author 10, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
59
Papers, trials and grants by year

2017: 2 papers · 2018: 9 papers · 2019: 6 papers · 2020: 6 papers · 2021: 2 papers · 2022: 12 papers · 2023: 1 paper · 2024: 1 paper · 2025: 5 papers · 2026: 2 papers

Papers 46

  1. Honokiol Inhibits Stemness in Pancreatic Cancer via Downregulating c-Met Expression. Co-author DOI 10.1002/ptr.70176↗
  2. MUC15 loss promotes perineural invasion in pancreatic cancer by activating the IGF1R/STAT3/NGF pathway. Co-author DOI 10.1016/j.canlet.2026.218362↗
  3. Endoscopic ultrasound elastography in solid pancreatic lesions: individual and combined performance of strain ratio, fat-lesion strain ratio, and mean strain h… Co-author DOI 10.1007/s10238-025-01969-5↗
  4. Characterization and treatment of brain metastases from pancreatic cancer: a systematic review. Co-author DOI 10.1007/s12672-025-02623-y↗
  5. NEAT1 promotes the perineural invasion of pancreatic cancer via the E2F1/GDNF axis. Co-author DOI 10.1016/j.canlet.2025.217497↗
  6. Elevated SREBP1 accelerates the initiation and growth of pancreatic cancer by targeting SOX9. Co-author DOI 10.1186/s13062-025-00595-1↗
  7. Tobacco carcinogen NNK promotes pancreatic cancer proliferation via LINC00857/β-catenin. Co-author DOI 10.18332/tid/203455↗
  8. Corrigendum to "2'-Hydroxyflavanone inhibits the progression of pancreatic cancer cells and sensitizes the chemosensitivity of EGFR inhibitors via repressing S… First author DOI 10.1016/j.canlet.2023.216602↗
  9. Mutant p53 driven-LINC00857, a protein scaffold between FOXM1 and deubiquitinase OTUB1, promotes the metastasis of pancreatic cancer. First author DOI 10.1016/j.canlet.2022.215976↗
  10. NNK from tobacco smoking enhances pancreatic cancer cell stemness and chemoresistance by creating a β2AR-Akt feedback loop that activates autophagy. Co-author DOI 10.1002/1878-0261.13230↗
  11. Heat shock factor 1 inhibition sensitizes pancreatic cancer to gemcitabine via the suppression of cancer stem cell-like properties. Co-author DOI 10.1016/j.biopha.2022.112713↗
  12. Corrigendum to " 2'-Hydroxyflavanone inhibits the progression of pancreatic cancer cells and sensitizes the chemosensitivity of EGFR inhibitors via repressing … First author DOI 10.1016/j.canlet.2022.215913↗
  13. Piezo1 act as a potential oncogene in pancreatic cancer progression. Co-author DOI 10.1016/j.lfs.2022.121035↗
  14. HGF/c-Met pathway facilitates the perineural invasion of pancreatic cancer by activating the mTOR/NGF axis. Co-author DOI 10.1038/s41419-022-04799-5↗
  15. Thiostrepton induces ferroptosis in pancreatic cancer cells through STAT3/GPX4 signalling. Co-author DOI 10.1038/s41419-022-05082-3↗
  16. Correction: Thiostrepton induces ferroptosis in pancreatic cancer cells through STAT3/GPX4 signalling. Co-author DOI 10.1038/s41419-022-05236-3↗
  17. Nodal Enhances Perineural Invasion in Pancreatic Cancer by Promoting Tumor-Nerve Convergence. Co-author DOI 10.1155/2022/9658890↗
  18. Integrated analysis of necroptosis-related lncRNAs for prognosis and immunotherapy of patients with pancreatic adenocarcinoma. Co-author DOI 10.3389/fgene.2022.940794↗
  19. Editorial: The Microenvironment in Pancreatic Cancer and Therapeutic Strategies Targeting Microenvironment. Co-author DOI 10.3389/fonc.2022.923982↗
  20. Huaier suppresses pancreatic cancer progression via activating cell autophagy induced ferroptosis. Last author DOI 10.3389/fonc.2022.960858↗
  21. RASAL2 mediated the enhancement of YAP1/TIAM1 signaling promotes malignant phenotypes of pancreatic ductal adenocarcinoma. Co-author DOI 10.7150/ijbs.72204↗
  22. Arl4c promotes the growth and drug resistance of pancreatic cancer by regulating tumor-stromal interactions. Co-author DOI 10.1016/j.isci.2021.103400↗
  23. The EGFR-HSF1 axis accelerates the tumorigenesis of pancreatic cancer. Co-author DOI 10.1186/s13046-020-01823-4↗
  24. Resveratrol slows the tumourigenesis of pancreatic cancer by inhibiting NFκB activation. Co-author DOI 10.1016/j.biopha.2020.110116↗
  25. Huaier extract restrains pancreatic cancer by suppressing Wnt/β-catenin pathway. Co-author DOI 10.1016/j.biopha.2020.110126↗
  26. 2'-Hydroxyflavanone inhibits the progression of pancreatic cancer cells and sensitizes the chemosensitivity of EGFR inhibitors via repressing STAT3 signaling. First author DOI 10.1016/j.canlet.2019.11.041↗
  27. Cav-1 Ablation in Pancreatic Stellate Cells Promotes Pancreatic Cancer Growth through Nrf2-Induced shh Signaling. Co-author DOI 10.1155/2020/1868764↗
  28. Resveratrol Ameliorates the Malignant Progression of Pancreatic Cancer by Inhibiting Hypoxia-induced Pancreatic Stellate Cell Activation. Co-author DOI 10.1177/0963689720929987↗
  29. NAF-1 Inhibition by Resveratrol Suppresses Cancer Stem Cell-Like Properties and the Invasion of Pancreatic Cancer. Co-author DOI 10.3389/fonc.2020.01038↗
  30. Hypoxia-driven paracrine osteopontin/integrin αvβ3 signaling promotes pancreatic cancer cell epithelial-mesenchymal transition and cancer stem cell-like proper… Co-author DOI 10.1002/1878-0261.12399↗
  31. Mouse-Derived Allografts: A Complementary Model to the KPC Mice on Researching Pancreatic Cancer In Vivo. First author DOI 10.1016/j.csbj.2019.03.016↗
  32. Resveratrol enhances the chemotherapeutic response and reverses the stemness induced by gemcitabine in pancreatic cancer cells via targeting SREBP1. First author DOI 10.1111/cpr.12514↗
  33. Pancreatic Stellate Cells Facilitate Perineural Invasion of Pancreatic Cancer via HGF/c-Met Pathway. Co-author DOI 10.1177/0963689719851772↗
  34. High glucose microenvironment accelerates tumor growth via SREBP1-autophagy axis in pancreatic cancer. First author DOI 10.1186/s13046-019-1288-7↗
  35. Betulinic acid inhibits stemness and EMT of pancreatic cancer cells via activation of AMPK signaling. Co-author DOI 10.3892/ijo.2018.4604↗
  36. Targeting glypican-4 overcomes 5-FU resistance and attenuates stem cell-like properties via suppression of Wnt/β-catenin pathway in pancreatic cancer cells. Co-author DOI 10.1002/jcb.27266↗
  37. Hyperglycemia aggravates microenvironment hypoxia and promotes the metastatic ability of pancreatic cancer. Co-author DOI 10.1016/j.csbj.2018.10.006↗
  38. Metformin suppresses tumor angiogenesis and enhances the chemosensitivity of gemcitabine in a genetically engineered mouse model of pancreatic cancer. Co-author DOI 10.1016/j.lfs.2018.07.046↗
  39. Paracrine HGF/c-MET enhances the stem cell-like potential and glycolysis of pancreatic cancer cells via activation of YAP/HIF-1α. Co-author DOI 10.1016/j.yexcr.2018.07.041↗
  40. Resveratrol-Induced Downregulation of NAF-1 Enhances the Sensitivity of Pancreatic Cancer Cells to Gemcitabine via the ROS/Nrf2 Signaling Pathways. Co-author DOI 10.1155/2018/9482018↗
  41. Overexpression of Gremlin 1 by sonic hedgehog signaling promotes pancreatic cancer progression. Co-author DOI 10.3892/ijo.2018.4573↗
  42. Itraconazole inhibits invasion and migration of pancreatic cancer cells by suppressing TGF-β/SMAD2/3 signaling. Co-author DOI 10.3892/or.2018.6281↗
  43. Metformin suppresses the invasive ability of pancreatic cancer cells by blocking autocrine TGF‑β1 signaling. First author DOI 10.3892/or.2018.6518↗
  44. Norepinephrine enhances cell viability and invasion, and inhibits apoptosis of pancreatic cancer cells in a Notch‑1‑dependent manner. Co-author DOI 10.3892/or.2018.6696↗
  45. Loss of AMPK activation promotes the invasion and metastasis of pancreatic cancer through an HSF1-dependent pathway. First author DOI 10.1002/1878-0261.12116↗
  46. Metformin suppresses cancer initiation and progression in genetic mouse models of pancreatic cancer. First author DOI 10.1186/s12943-017-0701-0↗

Closest collaborators

The 25 strongest of 59 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Qingyong Ma · 42 shared papers, 2017–2025 · strength 5.07
  2. Zheng Wang · 21 shared papers, 2019–2026 · strength 3.40
  3. Cancan Zhou · 21 shared papers, 2017–2025 · strength 2.32
  4. Zheng Wu · 17 shared papers, 2019–2025 · strength 2.19
  5. Wanxing Duan · 20 shared papers, 2017–2025 · strength 2.08
  6. Jiguang Ma · 18 shared papers, 2017–2025 · strength 1.81
  7. Tao Qin · 10 shared papers, 2018–2026 · strength 1.46
  8. Ying Xiao · 13 shared papers, 2018–2022 · strength 1.40
  9. Yangyang Yue · 9 shared papers, 2020–2026 · strength 1.36
  10. Zeen Zhu · 8 shared papers, 2022–2026 · strength 1.31
  11. Liang Cheng · 16 shared papers, 2017–2020 · strength 1.24
  12. Jie Li · 12 shared papers, 2017–2024 · strength 1.23
  13. Wunai Zhang · 7 shared papers, 2022–2026 · strength 1.19
  14. Junyu Cao · 13 shared papers, 2017–2019 · strength 0.98
  15. Simei Zhang · 6 shared papers, 2022–2026 · strength 0.97
  16. Tao Qin · 8 shared papers, 2018–2025 · strength 0.93
  17. Ke Chen · 11 shared papers, 2017–2022 · strength 0.91
  18. Jiantao Mo · 5 shared papers, 2022–2025 · strength 0.90
  19. Weifan Zhang · 6 shared papers, 2022–2023 · strength 0.87
  20. Zhengdong Jiang · 10 shared papers, 2017–2023 · strength 0.82
  21. Liang Han · 6 shared papers, 2018–2025 · strength 0.78
  22. Xuqi Li · 7 shared papers, 2018–2025 · strength 0.78
  23. Erxi Wu · 7 shared papers, 2018–2022 · strength 0.76
  24. Liankang Sun · 10 shared papers, 2017–2020 · strength 0.76
  25. Bin Yan · 10 shared papers, 2017–2019 · strength 0.74

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.